Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection - Wikidata - awgldk - TriplyDB

Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection

Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection

http://www.wikidata.org/entity/Q28472713

about

Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal transduction Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice Investigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.Novel pneumocystis antigen discovery using fungal surface proteomics.Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?Pneumocystis jirovecii detection in asymptomatic patients: what does its natural history tell us?Clearance of Pneumocystis murina infection is not dependent on MyD88 Genomic insights into the fungal pathogens of the genus pneumocystis: obligate biotrophs of humans and other mammals.Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.Comparative genomics suggests primary homothallism of Pneumocystis species.Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii.Pathological and protective immunity to Pneumocystis infection.Pneumocystis encodes a functional endo-β-1,3-glucanase that is expressed exclusively in cysts.The state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall.Colonization by Pneumocystis jirovecii and its role in disease.The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts.Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia A protracted course of Pneumocystis pneumonia in the setting of an immunosuppressed child with GMS-negative bronchoalveolar lavage Dectin immunoadhesins and pneumocystis pneumonia.The life cycle stages of Pneumocystis murina have opposing effects on the immune response to this opportunistic, fungal pathogen.Functional Characterization of Pneumocystis carinii Inositol Transporter 1.Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.Identification and Functional Ascertainment of the Pneumocystis jirovecii Potential Drug Targets Gsc1 and Kre6 Involved in Glucan Synthesis.Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for Therapy.Pneumocystis jirovecii colonization in Chronic Obstructive Pulmonary Disease (COPD).Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.β-Glucans Are Masked but Contribute to Pulmonary Inflammation During Pneumocystis Pneumonia.New advances in understanding the host immune response to Pneumocystis.Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.

P2860

Q24614334-29D247FB-8D68-4225-A498-F13B0715927C Q26851629-6FA0C2CD-ABEF-438F-825D-3CEBB4FF478A Q28477349-C1FAE3AF-CE55-4E28-A18E-546B982D6A92 Q28535112-FD92E0CC-B7B3-486C-BD11-EEFFFDF96FA1 Q29994504-EF935692-C30B-495E-90ED-34204AC91032 Q30248345-3941F3B8-2481-4397-803B-0118A9DE44A6 Q33603055-002BD405-2B31-46FD-AC03-CF27E2D6ECEF Q33707383-08A40CEB-E7D2-416D-B741-1E9507963FDA Q33777831-BFBB7F87-7E69-45F9-88EB-441A47025302 Q33807392-9DCB885A-7368-47CE-A897-08A706ABB863 Q34466417-4F05EC58-7A9C-4ED2-B6C0-88E7BB64B955 Q34788828-6BFEAA7F-9C2E-4008-98FE-3E68CDC528FB Q35038258-9860B012-27CC-41AF-859D-787AECBF6171 Q35040362-D22B877C-883C-492E-B38C-DAF237D7CABF Q35084980-74B495CB-231A-4C37-A054-40372E37CEA2 Q35102593-E6852E28-3987-4640-94A4-30752ECE7BE6 Q35739010-B9C3A215-8F54-41CF-ADA0-5126D256403B Q35745569-EDE4B909-9CD5-42D5-974F-10D3D94EA651 Q35940586-52D48DEC-E3EE-4B69-B316-194319AA190F Q36082802-A400387D-2D67-43B6-95F1-CD7550684F25 Q36190142-5F93BD86-AA79-488A-9533-9D51F19BD8E1 Q36288984-B043DDC6-9CE3-4AF1-BC05-7BACF3D58C5A Q36611073-06B9C9B3-8773-435B-9562-BF087ED07011 Q36744771-7BB8F6E1-429C-4F34-91E5-B2288076B947 Q36871231-B5AD13C1-D244-43B6-AC0B-B56C168461A6 Q37123798-B16F0234-C2A3-41DF-B274-909B0AF49347 Q37345920-18D91F2A-FB96-4774-B519-B48BE7350B4B Q37502936-E1E79BC7-D110-4D10-9966-F9DD73DEBBD8 Q38039139-AD75EA13-788C-499A-B417-10D445C89C92 Q38191294-D8555A35-19B2-4E42-886C-D1BE8136727C Q38934525-3453CF48-0DFE-4545-9DCA-21C77666F67F Q39177044-8F898708-9AA5-404B-9577-C18F9F65DB4E Q39386157-BE51A93E-E476-437F-B18A-9CFE4332BAE9 Q39417008-85C054B9-3800-4543-B73F-D7D8CA9A06FF Q40092648-E3785923-9873-4E14-ACC0-CBCF5D7731F9 Q42049712-05322075-797A-49C1-BC52-8FDC2329E818 Q46516900-13FDC5D7-AD71-4624-9C30-0E52CE801BCA Q47205373-3BE4C54C-0DD9-45EA-9C91-11E1ABBB3A71 Q47563983-F257676E-654F-4AEC-B70D-CB0C5C1592C1 Q48149271-496FF66A-3829-4C54-8008-6C61E1D6B4B3

P2860

Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection

http://www.wikidata.org/entity/Q28472713

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Echinocandin treatment of pneu ...... cannot transmit the infection

@ast

Echinocandin treatment of pneu ...... cannot transmit the infection

@en

Echinocandin treatment of pneu ...... cannot transmit the infection

@nl

type

label

Echinocandin treatment of pneu ...... cannot transmit the infection

@ast

Echinocandin treatment of pneu ...... cannot transmit the infection

@en

Echinocandin treatment of pneu ...... cannot transmit the infection

@nl

prefLabel

Echinocandin treatment of pneu ...... cannot transmit the infection

@ast

Echinocandin treatment of pneu ...... cannot transmit the infection

@en

Echinocandin treatment of pneu ...... cannot transmit the infection

@nl

P1433

Q28472713-57A8FF08-74FC-4E5D-BB3A-3279EE084E55

P1476

Q28472713-E12AF3E5-8434-4FD4-930D-F604C8ABD609

P2093

Q28472713-1FD9993D-EB41-4542-984B-0BF58A3528FA

Q28472713-5A4DD8B0-B2CB-4350-9C17-06DD51EA039C

Q28472713-69D12D6A-A3B9-4AEB-A9C3-13982DF38624

Q28472713-6E5F92CF-2D68-4A94-B8B1-6D981E4DFA7A

Q28472713-7F0E659A-543E-4276-BB1F-3FDEAEC84DE3

Q28472713-BE04ABEC-356A-4B04-ACC6-9D938B045A02

Q28472713-E4A19DD7-84A3-4ECF-98DA-87CFE94D6E93

P2860

Q28472713-01B4C3A7-6348-474E-AD89-E6D02C5BD4BA

Q28472713-04BBC4D0-3FC3-4D52-9F11-577F82CB0039

Q28472713-08D3D49F-4AA2-4F72-A6A2-FA08698CB6D5

Q28472713-1E606EFF-A9CB-4140-B97A-F6882D72CAF9

Q28472713-2856E5E4-68F4-4747-91B3-CD9ADEF2301B

Q28472713-2CE53124-1DC2-4F33-B32B-72E2739066D2

Q28472713-2D764904-D8D8-40C8-B4D9-EEB685700693

Q28472713-34C95243-6CB0-47D0-8756-A38F43E12CA0

Q28472713-3A12612E-C0AF-45CB-9414-76FD4AB8D17A

Q28472713-3D747970-9071-4C20-95F5-D496B7F916E5

P304

Q28472713-01E348D6-3C16-4A12-8435-940FC9F559B6

P31

Q28472713-71FC8FB4-30C5-4722-9DE5-52A140B400C9

P3181

Q28472713-CC58D895-E49B-44BF-923F-26FAE9B75A6E

P356

Q28472713-9EFA7767-0AAB-4CA2-A570-DF3AACA1478B

P407

Q28472713-213D96B4-9882-4BB1-BFA4-CFAB29185683

P433

Q28472713-E9D4210B-D488-4744-8EA6-5AA51C2C91E6

P478

Q28472713-33447700-890D-4CB8-B738-B9C634A61957

P50

Q28472713-1DA5FC1A-25B0-45BF-B60C-693FCDCDA926

P577

Q28472713-E74E8B59-6938-477A-B29E-A3C3C889EFF4

P5875

Q28472713-5B59A93B-4414-4081-953D-17B84F12DB1C

P698

Q28472713-B24568FF-C3FC-4EEA-A182-85F41888861A

P921

Q28472713-15293E62-E1FE-4DA9-93E6-22193C923072

P932

Q28472713-5CBB576E-4B93-441B-B3D5-CC23C02CE4F6

P3181

P356

JOURNAL.PONE.0008524

P1433

P1476

Echinocandin treatment of pneu ...... cannot transmit the infection

@en

P2093

Alan Ashbaugh

http://www.w3.org/2001/XMLSchema#string

Keeley Lynch

http://www.w3.org/2001/XMLSchema#string

Margaret S Collins

http://www.w3.org/2001/XMLSchema#string

Michael J Linke

http://www.w3.org/2001/XMLSchema#string

Peter D Walzer

http://www.w3.org/2001/XMLSchema#string

Ronald Brubaker

http://www.w3.org/2001/XMLSchema#string

Tom Sesterhenn

http://www.w3.org/2001/XMLSchema#string

P2860

A drug-sensitive genetic network masks fungi from the immune system

Transcriptome of Pneumocystis carinii during fulminate infection: carbohydrate metabolism and the concept of a compatible parasite

Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display

Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia

Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment

Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome.

Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003.

Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer

P304

e8524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2587678

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0008524

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Melanie T. Cushion

P577

2010-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41401460

http://www.w3.org/2001/XMLSchema#string

P698

20126455

http://www.w3.org/2001/XMLSchema#string

P921

P932

2813285

http://www.w3.org/2001/XMLSchema#string